Company profile: Tango Therapeutics
1.1 - Company Overview
Company description
- Provider of next-generation cancer therapies leveraging synthetic lethality, including TNG908 and TNG462, PRMT5 inhibitors for MTAP-deleted cancers; TNG260, a CoREST inhibitor aimed at reversing immune evasion in STK11-mutant cancers; and TNG348, a USP1 inhibitor for BRCA1/2-mutant and other HRD+ cancers, all in Phase 1/2 trials. Also provides a CRISPR-based functional genomics platform to identify synthetic lethal targets.
Products and services
- Synthetic Lethality Discovery Platform: High-throughput CRISPR-based functional genomics system mapping synthetic lethal targets in cancer cells harboring specific tumor suppressor gene loss for precise target identification
- TNG908: Clinical-stage engineered synthetic lethal PRMT5 inhibitor for MTAP-deleted cancers, tested in Phase 1/2 trials with targeted inhibition of PRMT5 in MTAP-loss contexts
- TNG260: Clinical-stage CoREST inhibitor architected to reverse immune evasion in STK11-mutant cancers, currently evaluated in Phase 1/2 clinical trials
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tango Therapeutics
NuGEN
HQ: United States
Website
- Description: Provider of innovative genomics sample preparation solutions enabling scientists to access true biology in all samples, independent of type, quality and amount, for analysis on leading analytical platforms, ensuring robust and reproducible results for researchers seeking to predict disease
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NuGEN company profile →
CellforCure
HQ: France
Website
- Description: Provider of advanced therapy medicinal product expertise as a key industrial and innovative player in the field.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CellforCure company profile →
Variant Bio
HQ: United States
Website
- Description: Provider of genomics-driven drug discovery, using whole-genome sequencing and custom algorithms to identify novel, population-specific variants and disease-relevant targets. Offers research partnerships, benefit-sharing programs, and an Affordable Medicines Pledge, plus the Variant Bio Standley Fellowship for genomic data analysis and partnerships with populations with specific health-related traits.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Variant Bio company profile →
4basebio
HQ: Germany
Website
- Description: Provider of DNA manufacturing technologies and products for the gene therapy market, including double-stranded DNA formats: hpDNA (hairpinned ends for viral and non-viral vectors), osDNA (with nucleotide modifications for degradation resistance and tunable immunostimulation for DNA vaccines), opDNA and oeDNA for mRNA production and genome editing, the Hermes non-viral delivery platform, and DNA template manufacturing for AAV/Lentivirus with small-scale AAV production and purification.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4basebio company profile →
Singular Bio
HQ: United States
Website
- Description: Provider of single molecule detection technology enabling single-molecule analysis of a patient's DNA with high sensitivity for detecting many common conditions, aimed at expanding access to fundamental healthcare information by making advanced genetic tests available to everyone.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Singular Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tango Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tango Therapeutics
2.2 - Growth funds investing in similar companies to Tango Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tango Therapeutics
4.2 - Public trading comparable groups for Tango Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →